We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+4.77%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$4.49B
AUM Growth
+$287M
Cap. Flow
+$532M
Cap. Flow %
11.84%
Top 10 Hldgs %
50.53%
Holding
128
New
23
Increased
12
Reduced
25
Closed
8

Top Buys

Rank Stock Value
1
DSGN icon
Design Therapeutics
DSGN
+$173M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$75.9M
3
NVAX icon
Novavax
NVAX
+$49.8M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$43.3M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$42.5M

Top Sells

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$71.6M
2
VIE
Viela Bio, Inc. Common Stock
VIE
+$51.4M
3
IMVT icon
Immunovant
IMVT
+$32.3M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$30.6M
5
KURA icon
Kura Oncology
KURA
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 75%
2 Financials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
51
Zai Lab
ZLAB
$2.62B
$20M 0.45%
150,000
-39,092
-21% -$6.05M
TCRR
52
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$19.9M 0.44%
900,000
+400,000
+80% +$10.9M
KALV
53
DELISTED
KalVista Pharmaceuticals
KALV
$19.3M 0.43%
+750,000
New +$19.7M
HGEN
54
DELISTED
HUMANIGEN, INC.
HGEN
$19.1M 0.43%
+1,000,000
New +$18.3M
CNTB
55
Connect Biopharma Holdings
CNTB
$139M
$18.5M 0.41%
+1,000,000
New +$17M
OMER icon
56
CALL
Omeros
OMER
$959M
$17.8M 0.4%
1,000,000
– –
ALBO
57
DELISTED
Albireo Pharma Inc
ALBO
$17.6M 0.39%
500,000
– –
INSP icon
58
Inspire Medical Systems
INSP
$1.74B
$17.6M 0.39%
85,000
-15,000
-15% -$3.19M
ELDN icon
59
Eledon Pharmaceuticals
ELDN
$285M
$15.1M 0.34%
1,415,500
– –
RPTX
60
DELISTED
Repare Therapeutics
RPTX
$14.2M 0.32%
462,205
+162,205
+54% +$5.51M
ANAB icon
61
AnaptysBio
ANAB
$1.68B
$14M 0.31%
650,000
– –
BEAM icon
62
Beam Therapeutics
BEAM
$2.84B
$13.7M 0.31%
171,775
-752,474
-81% -$71.6M
BHVN
63
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$13.7M 0.3%
200,000
-225,000
-53% -$18.2M
FHTX icon
64
Foghorn Therapeutics
FHTX
$360M
$13.2M 0.29%
1,000,000
– –
DMRA
65
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$13.1M 0.29%
86,029
– –
ASND icon
66
Ascendis Pharma A/S
ASND
$16.8B
$12.9M 0.29%
100,000
– –
HARP
67
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$11.9M 0.27%
57,060
– –
AXSM icon
68
Axsome Therapeutics
AXSM
$10.9B
$11.3M 0.25%
200,000
– –
TBPH icon
69
Theravance Biopharma
TBPH
$877M
$11.2M 0.25%
550,000
– –
AVEO
70
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$11M 0.24%
+1,500,000
New +$12.9M
BNTX icon
71
BioNTech
BNTX
$23.5B
$10.9M 0.24%
100,000
-175,000
-64% -$18.6M
ITOS
72
DELISTED
iTeos Therapeutics
ITOS
$10.3M 0.23%
300,000
– –
INSM icon
73
Insmed
INSM
$28.6B
$10.2M 0.23%
300,000
– –
SWTX
74
DELISTED
SpringWorks Therapeutics
SWTX
$9.2M 0.2%
125,000
– –
OBIO icon
75
Orchestra BioMed
OBIO
$254M
$8.98M 0.2%
800,000
– –
1 2
3
4 5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Cormorant Asset Management held 128 positions worth $4.49B, up 6.8% from $4.2B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Cormorant Asset Management deployed $532M of net new capital in Q1 2021, opening 23 new positions and adding to 12 existing holdings. Its largest new stake was Design Therapeutics: 5,114,850 shares worth $146M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Beam Therapeutics, an estimated $71.6M trimmed.

  • Cormorant Asset Management's largest Q1 2021 buy was Design Therapeutics: 5,114,850 shares worth $146M.
  • Cormorant Asset Management added most to Turning Point Therapeutics, Inc. Common Stock in Q1 2021, an estimated $42.5M increase.
  • Cormorant Asset Management's biggest Q1 2021 reduction was Beam Therapeutics, cutting an estimated $71.6M.
  • Cormorant Asset Management fully exited Viela Bio, Inc. Common Stock in Q1 2021, selling an estimated $51.4M.
  • Cormorant Asset Management's ten largest holdings make up 51% of its $4.49B portfolio in Q1 2021.
  • Cormorant Asset Management opened 23 new positions and closed 8 in Q1 2021.
  • Cormorant Asset Management's portfolio value rose 6.8% quarter-over-quarter to $4.49B.

Based on Cormorant Asset Management's 13F filing for Q1 2021, filed 17 May 2021.